Rocket Pharmaceuticals ... Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based ...
On Wednesday, Stifel analysts reiterated their Buy rating and $27.00 price target for Rocket Lab USA (NASDAQ:RKLB) shares, which ...
Rocket Lab USA has a jam-packed 2025 schedule filled with new launches as well as acquisitions. Check out why I'm initiating ...
BMO Capital Markets assumed coverage on shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) in a report released on Wednesday morning, Ratings reports. The brokerage issued an outperform ...
Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) have been given an average rating of “Moderate Buy” by the twelve analysts that are currently covering the company, Marketbeat ...
On Thursday, BofA Securities increased its price target for Rocket Lab USA (NASDAQ:RKLB) shares, setting a new goal of $30, up ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback